To assess efficacy and safety of bivalirudin during PCI therapy in AMI patients with Heparin-Induced Thrombocytopenia(HIT).Methods
488 patients were enrolled which comfirmed AMI by coronary angiography from July, 2012 to February, 2013, in which 10 patients were induced to come out Heparin-Induced Thrombocytopenia, 6 females, aged 48–79 years. The incidence of HIT patients was 2.0%. All patients were applied to bivalirudin (0.25 g, intravenous injection) during PCI. We summarised the characteristics of the patients, record incidence of in-hospital minor bleeding, major bleeding, platelet reduction and incidence of major adverse cardiac events (MACE) during hospitalisation and 1 month after discharge.Results
(1) There are no difference of primary endpoint (the blood platelet count of pre-PCI vs after PCI, (120.7 ± 43.2)109/L vs (137.2 ± 48.9)10 × 9/L, p > 0.05). (2) Successful rate of immediate post-procedure was 100%. (3) Safety: Hospitalisation and follow-up of 30 d, 10 patients had no life-threatening haemorrhage and MACE.Conclusions
bivalirudin, which can protect the activity of platelet, decrease mortality and mild haemorrhage, is feasible and safe for the patients with AMI during PCI therapy.